Distinct Genetic and Immunological Features in Patients With Onset of IDDM Before and After Age 40
-
- Tobias Lohmann
- Department of Internal Medicine III Leipzig, Germany
-
- Jochen Sessler
- Department of Internal Medicine III Leipzig, Germany
-
- Hans-Joachim Verlohren
- University of Leipzig Diabetes Specialty Practice, Leipzig, Germany
-
- Sabine Schröder
- Institute of Clinical Immunology and Transfusion Medicine Leipzig, Germany
-
- Julia Rötger
- Department of Internal Medicine III Leipzig, Germany
-
- Karsten Dãhn
- Department of Internal Medicine III Leipzig, Germany
-
- Nils Morgenthaler
- Department of Internal Medicine III Leipzig, Germany
-
- Werner A Scherbaum
- Department of Internal Medicine III Leipzig, Germany
この論文をさがす
説明
<jats:sec> <jats:title>OBJECTIVE</jats:title> <jats:p>Young age at onset is a relevant parameter associated with a rapid progression of IDDM. Our major aim was to define differences between IDDM patients with age at diagnosis > 40 years and adult IDDM with onset at a younger age.</jats:p> </jats:sec> <jats:sec> <jats:title>RESEARCH DESIGN AND METHODS</jats:title> <jats:p>The correlation between islet-related antibodies (islet cell antibodies [ICAs] and antibodies [Abs] to GAD and the tyrosine phosphatase IA2), T-cell responses to GAD peptides and HLA class II isotypes was investigated in 23 IDDM patients 12–38 years of age at onset (group 1), 24 patients with IDDM > 40 years of age at onset (group 2), and 12 healthy control subjects. ICAs were measured by indirect immunofluorescence, and GAD-Ab and IA2-Ab were measured by immunoprecipitation tests. T-cell responses against GAD peptides, which had been identified as typical for IDDM, were tested by 5-day proliferation assays. HLA class II alleles were typed by polymerase chain reaction.</jats:p> </jats:sec> <jats:sec> <jats:title>RESULTS</jats:title> <jats:p>ICAs and GAD-Abs were more prevalent in IDDM patients than in control subjects (P < 0.001), but only IDDM group 1 had IA2-Abs (P < 0.001 compared with IDDM group 2 and control subjects). Moreover, antibody combinations differed between IDDM patients of groups 1 and 2. T-cell responses to GAD peptides were seen in 67% of IDDM group 1 and in 71% of IDDM group 2 (P < 0.02 compared with control subjects). IDDM patients of group 1 were more frequently DR4+/DQ8+ and less frequently DR2+/DQ0602+ compared with IDDM patients of group 2 (P < 0.05).</jats:p> </jats:sec> <jats:sec> <jats:title>CONCLUSIONS</jats:title> <jats:p>Our data provide strong evidence for humoral and cellular autoimmunity in adult IDDM patients with onset both before and after 40 years of age. However, late-onset differs from young-onset IDDM with respect to Ab profiles, especially a lack of IA2-Ab, and HLA class II types. These findings have consequences for the diagnostic strategy for identifying slow-onset IDDM in individuals after 40 years of age.</jats:p> </jats:sec>
収録刊行物
-
- Diabetes Care
-
Diabetes Care 20 (4), 524-529, 1997-04-01
American Diabetes Association
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1361418519317401728
-
- NII論文ID
- 30026279623
-
- NII書誌ID
- AA00160920
-
- ISSN
- 19355548
- 01495992
- http://id.crossref.org/issn/01495992
-
- データソース種別
-
- Crossref
- CiNii Articles